Results 31 to 40 of about 1,043 (146)

Anti-CMV therapy, what next? A systematic review

Frontiers in Microbiology, 2023
Human cytomegalovirus (HCMV) is one of the main causes of serious complications in immunocompromised patients and after congenital infection. There are currently drugs available to treat HCMV infection, targeting viral polymerase, whose use is ...
Claire Gourin, Sophie Alain, Sophie Alain, Sébastien Hantz, Sébastien Hantz   +4 more
doaj   +1 more source

Retrospective chart review of transplant recipients with cytomegalovirus infection who received maribavir in the Phase 3 SOLSTICE trial: Data at 52 weeks post-maribavir treatment initiation

Antiviral Therapy, 2023
Background Cytomegalovirus (CMV) infection is a frequent complication in haematopoietic cell/solid organ transplant (HCT/SOT) recipients. Previous studies report all-cause mortality rates of 31% and 50% in HCT/SOT recipients post-treatment initiation ...
Marielle Bassel, Dorothy Romanus, Tien Bo, Aimee K Sundberg, Sandra Okala, Ishan Hirji   +5 more
doaj   +1 more source

Unraveling Cytomegalovirus Drug Resistance in Transplant Patients by Targeting Deep Sequencing. [PDF]

J Med Virol
ABSTRACT Drug‐resistant cytomegalovirus (CMV) poses a major clinical challenge in transplant recipients, leading to treatment failure and increased morbidity. This study applied a next‐generation sequencing (NGS) approach to identify antiviral resistance mutations (ARMs) in 71 samples from 68 CMV‐positive patients who had undergone hematopoietic stem ...
Alemán S, Camacho J, Recio V, Ruiz E, Zamarrón P, Anel J, Enjuto M, Tarragó D.   +7 more
europepmc   +2 more sources

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models. [PDF]

Mol Oncol
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Classon J, Stenudd M, Zamboni M, Alkass K, Eriksson CJ, Pedersen L, Schörling A, Thoss A, Bergh A, Wikström P, Adami HO, Sørensen HT, Druid H, Frisén J.   +13 more
europepmc   +2 more sources

Use of Maribavir for Multidrug-Resistant Cytomegalovirus in an Immunocompromised Host With HIV and Common Variable Immunodeficiency

Annals of Internal Medicine: Clinical Cases
We present a case of multidrug-resistant Cytomegalovirus (CMV) and the use of maribavir, a novel oral treatment of resistant CMV, in a nontransplant immunocompromised host. Our patient initially was diagnosed with CMV pharyngitis on biopsy.
Diana Zarowin, Jared Coe, Maxwell Bressman, Paul Riska, Philip Yune, Ghaleb Halaseh, Matthew J. Akiyama   +6 more
doaj   +1 more source

Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection

Viruses, 2022
Cytomegalovirus (CMV), a member of the Herpesviridae family, is frequent among hematopoietic cell transplant (HCT) and solid organ transplant (SOT) recipients in absence of antiviral prophylaxis, and is a major cause of morbidity and mortality in these ...
Christopher P. Ouellette
doaj   +1 more source

New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease

Infectious Diseases and Therapy, 2022
Cytomegalovirus (CMV) infection can have both direct and indirect effects after solid-organ transplantation, with a significant impact on transplant outcomes.
Camille Nelson Kotton, Nassim Kamar
doaj   +1 more source

Effect of Ketoconazole on the Pharmacokinetics of Maribavir in Healthy Adults [PDF]

Antimicrobial Agents and Chemotherapy, 2008
ABSTRACT Maribavir, an oral antiviral drug with activity against cytomegalovirus, is currently undergoing studies to assess its efficacy and safety as cytomegalovirus prophylaxis following stem cell or solid organ transplantation. The main objective of this study was to assess the effects of oral ketoconazole, a potent inhibitor of the ...
D Ronald, Goldwater, Carolyn, Dougherty, Mary, Schumacher, Stephen A, Villano   +3 more
openaire   +2 more sources

Congenital CMV Infection: Determination of Transplacental Passage of Aciclovir by Ex Vivo Placental Perfusion

BJOG: An International Journal of Obstetrics &Gynaecology, Volume 133, Issue 6, Page 1241-1248, May 2026.
ABSTRACT Objective To quantify the transplacental transfer of aciclovir at an amount equivalent to 2 g of valaciclovir corresponding to the fractionated dosing regimen given four times daily used to reduce congenital cytomegalovirus (CMV) transmission and to treat the CMV‐infected fetus. Design Experimental ex vivo study.
Helyett Ollivier, Valentine Faure Bardon, Leo Froelicher Bournaud, Isidore Gaubert, Tiffany Guilleminot, Marianne Leruez‐Ville, Jean‐Marc Treluyer, Yves Ville, Gabrielle Lui, Julien Stirnemann   +9 more
wiley   +1 more source

Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. [PDF]

PLoS Pathogens, 2007
A process of pseudomitosis occurs during human cytomegalovirus infection that appears similar to cellular mitosis but involves the formation of multiple spindle poles, abnormal condensation, and mislocalization of chromosomal DNA.
Laura Hertel, Sunwen Chou, Edward S Mocarski   +2 more
doaj   +1 more source